Tiffany Thorn

Tiffany Thorn has a diverse range of work experience in the biotech and healthcare industries. Tiffany is the Founder and CEO of BiVictriX Therapeutics Ltd, a UK-based biotech company focused on oncology. With their leadership, the company is developing a new class of bispecific Antibody Drug Conjugates with superior potency and selectivity. Prior to this role, Tiffany worked as a Marketing and Licensing Manager at ADC Biotechnology Ltd, where they played a key role in marketing and licensing initiatives. Tiffany also has experience in the NHS, serving as a Clinical Immunologist and Chair of the North West Healthcare Science Trainee Network Board. Additionally, Tiffany has worked as a Synthetic Organic Chemist and Project Manager at RedX Pharma. Currently, they serve as a Board Trustee for Action AML UK and The UK Sepsis Trust.

Tiffany Thorn has a strong education background in the field of science. From 2007 to 2009, they attended Lancaster University, where they obtained a First Class Honours BSc in Biochemistry with Biomedicine. Following this, they pursued further education at The University of Manchester from 2011 to 2014, where they earned a Master's degree in Clinical Immunology with Histocompatibility and Immunogenetics. In addition to their formal education, Tiffany Thorn has also obtained certification as a Clinical Scientist with registration from the HCPC Registered institution.